Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Agennix Halves Headcount, Closes Houston Site, Following Talactoferrin Failure In NSCLC

This article was originally published in The Pink Sheet Daily

Executive Summary

German biotech Agennix makes drastic cuts following second late-stage clinical trial failure of its investigational oral immunotherapy talactoferrin.

You may also be interested in...

Wealthy Families Play A Growing Role in European Biotech Financing

The continued dearth of venture capital in Europe is highlighting the key role played by wealthy families as an alternative – or at least complementary – source of finance for biopharmaceutical firms.

Financings Of The Fortnight: Finding Comedy In Today's Financial Environment

A Magic 8-Ball assesses the Sanofi/Genzyme intrigue, while Convergence, Agennix, Tobira and CtyomX highlight a busy two weeks in biotech finance.

Novartis And Antisoma's ASA404 Stumbles Badly In A Phase III Lung Cancer Trial

Prospects for what was thought to be a promising first-in-class lung cancer treatment dim after a Phase III trial is halted early due to futility of improving survival.

Related Content


Related Companies




Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts